Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a phase 1b/2a trial.
The treatment was generally well tolerated, with mostly mild to moderate gastrointestinal side effects, supporting further investigation in larger, longer studies.